Mechanisms for Cisplatin-FUra Synergism and Cisplatin Resistance in Human Ovarian Carcinoma Cells both in vitro and in vivo

  • K. J. Scanlon
  • Y. Lu
  • M. Kashani-Sabet
  • J. x. Ma
  • E. Newman
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 131)


Cisplatin and FUra act synergisticly in human carcinomas. An increase in the availability of reduced folates necessary for tight binding of FdUMP to thymidylate synthase (TS) contributes to the enhanced cytotoxicity of this drug combination. The human ovarian A2780 cell line made three-fold resistant to cisplatin has been shown to have a three-fold elevation of m-RNA for dihydrofolate reductase (DHFR) and TS. However, this increase did not result from an amplification of the genes for these two enzymes. In contrast, ovarian carcinoma cells from patients who failed treatment with cisplatin and FUra have been shown to have both enhanced gene expression and increased gene copy number for DHFR and TS.


A2780 Cell Human Colon Carcinoma Cell Human Ovarian Carcinoma Cell Ovarian Carcinoma Patient Increase Gene Copy Number 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    B. Rosenberg, Fundamental studies with cisplatin, Cancer. 55: 2303 (1985).PubMedCrossRefGoogle Scholar
  2. 2.
    R. F. Ozols and R. C. Young, Chemotherapy of ovarian cancer, Sem. in Oncol. 11:257 (1984).Google Scholar
  3. 3.
    F. M. Schabel, H. E. Skipper, M. W. Trader, W. R. Laster, D. P. Griswold, and T. H. Corbett, Establishment of cross-resistance profiles for new agents, Cancer Treat. Rea. 67: 905 (1983).Google Scholar
  4. 4.
    A. Rosowsky, J. E. Wright, C. A. Cucchi, J. L. Flatow, D. H. Trites, B. A. Teicher, and E. Frei, Collateral methotrexate resistance in cultured human head and neck carcinoma cells selected for resistance to cis-diamminedichloroplatinum(II), Cancer Res. 47: 5913 (1987).PubMedGoogle Scholar
  5. 5.
    E. M. Newman, Y. Lu, M. Kashani-Sabet, V. Kesavan, and K. J. Scanlon, Biochemical basis for cisplatinum resistance in human ovarian carcinoma cells, Biochem. Pharm. 37: 443 (1988).PubMedCrossRefGoogle Scholar
  6. 6.
    Y. Lu, J. Han, and K. J. Scanlon, Biochemical and molecular properties of cisplatin resistance in A2780 cells grown in folinic acid, J. Biol. Chem. 263: 4891 (1988).PubMedGoogle Scholar
  7. 7.
    K. J. Scanlon, M. Kashani-Sabet, A. R. Cashmore, M. Pallai, B. A. Moroson, and M. Saketos, The role of methionine in methotrexate sensitive and resistant mouse leukemia L1210 cells, Cancer Chemother. Pharm. 19: 25 (1987).CrossRefGoogle Scholar
  8. 8.
    K. J. Scanlon, R. Safirstein, H. Thies, R. B. Gross, S. Waxman, and J. B. Guttenplan, Inhibition of amino acid transport by cisplatin and its derivatives in L1210 murine leukemia cells, Cancer Res. 43: 4211 (1983).PubMedGoogle Scholar
  9. 9.
    K. J. Scanlon, E. M. Newman, Y. Lu, and D. G. Priest, Biochemical basis for cisplatinum and 5-fluorouracil synergism in human ovarian carcinoma cells, Proc. Natl. Acad. Sci. USA 83: 8923 (1986).PubMedCrossRefGoogle Scholar
  10. 10.
    K. J. Scanlon and M. Kashani-Sabet, Elevated expression of dTMP synthase cycle genes in cisplatin-resistant A2780 cells, Proc. Natl. Acad. Sci. USA 85: 650 (1988).PubMedCrossRefGoogle Scholar
  11. 11.
    J. Chen and K. J. Scanlon, Molecular and biochemical properties of cisplatin-resistant HCT8 human colon carcinoma cells, Amer. Assoc. Cancer Res. 29: 1431 (1988).Google Scholar
  12. 12.
    A. Eva, K. C. Robbins, P. R. Andersen, A. Srinivasan, S. R. Tronick, E. P. Reddy, N. W. Ellmore, A. T. Galen, J. A. Lantenberger, T. S. Papas, E. H. Westin, F. Wong-Stall, R. C. Gallo, and S. A. Aaronson, Cellular genes analogous to retroviral one genes are transcribed in human tumour cells, Nature, Lond. 295: 116 (1982).CrossRefGoogle Scholar
  13. 13.
    B. J. Rollins, and C. D. Stiles, Regulation of c-myc and c-fos proto-oncogene expression by animal cell growth factors, In Vitro Cellular and Developmental Biol. 24: 81 (1988).CrossRefGoogle Scholar
  14. 14.
    M. Kashani-Sabet, J. J. Rossi, Y. Lu, J. Chen, H. Miyachi, J. x. Ma, D.Blaney, L. Leong, and K. J. Scanlon, Early detection of cisplatin resistance in fresh human carcinoma cells by in vitro enzymatic amplification assay, Amer. Assoc. Cancer Res. 29: 1159 (1988).Google Scholar
  15. 15.
    M. D. Sklar, Increased resistance to cis-diamminedichloroplatinum(II) in NIH 3TE cells transformed by ras oncogenes, Cancer Res. 48: 793 (1988).PubMedGoogle Scholar
  16. 16.
    L. Vanhamme and C. Szpirer, Methionine metabolism defect in cells transfected with an activated HRAS1 oncogene, Exp. Cell Res. 169: 120 (1987).PubMedCrossRefGoogle Scholar
  17. 17.
    R. B. Gross and K. J. Scanlon, Membrane transport properties of L1210 cells resistant to cisplatin, Chemoterapia 5: 37 (1986).Google Scholar
  18. 18.
    S. Shionoya, Y. Lu, and K. J. Scanlon, Properties of amino acid transport systems in K562 cells sensitive and resistant to cis-diamminedichloroplatinum(II), Cancer Res. 46: 3445 (1986).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • K. J. Scanlon
    • 1
  • Y. Lu
    • 1
  • M. Kashani-Sabet
    • 1
  • J. x. Ma
    • 1
  • E. Newman
    • 2
  1. 1.Section of Biochemical PharmacologyMedical OncologyDuarteUSA
  2. 2.Division of PediatricsCity of Hope National Medical CenterDuarteUSA

Personalised recommendations